Improving Delivery – Exenatide LAR
Unique opportunity for long-acting formulation
- Glucose-dependent actions
- Potent with long half-life
Formulation identified in 2003
- Potential for 1x / week to 1x / month dosing
Program managed by Amylin-Lilly Alliance and Alkermes